Literature DB >> 15522470

An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.

Eric J Velazquez1, Gary S Francis, Paul W Armstrong, Phillip E Aylward, Rafael Diaz, Christopher M O'Connor, Harvey D White, Marc Henis, Lois M Rittenhouse, Rakhi Kilaru, Wiek van Gilst, Georg Ertl, Aldo P Maggioni, Jiri Spac, W Douglas Weaver, Jean-Lucien Rouleau, John J V McMurray, Marc A Pfeffer, Robert M Califf.   

Abstract

AIMS: We analysed the contemporary incidence, outcomes, and predictors of heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) before discharge in patients with acute myocardial infarction (MI). The baseline presence of HF or LVSD, or its development during hospitalisation, increases short- and long-term risk after MI, yet its incidence, predictors, and outcomes have not been well described in a large, international, general MI population. METHODS AND
RESULTS: The VALIANT registry included 5573 consecutive MI patients at 84 hospitals in nine countries from 1999 to 2001. A multivariable logistic survival model was constructed using baseline variables to determine the adjusted mortality risk for those with in-hospital HF and/or LVSD. Baseline variables were also tested for associations with in-hospital HF and/or LVSD. Of the 5566 patients analysed, 42% had HF and/or LVSD during hospitalisation. Their in-hospital mortality rate was 13.0% compared with 2.3% for those without HF and/or without LVSD. After adjustment for other baseline risk factors, in-hospital HF and/or LVSD carried a hazard ratio for in-hospital mortality of 4.12 (95% confidence interval: 3.08-5.56). Patients with HF and/or LVSD also had disproportionately higher rates of other cardiovascular events.
CONCLUSIONS: HF and/or LVSD is common in the general contemporary MI population and precedes 80.3% of all in-hospital deaths after MI. Survivors of early MI-associated HF and/or LVSD have more complications, longer hospitalisations, and are more likely to die during hospitalisation. Although baseline variables can identify MI patients at highest risk for HF and/or LVSD, such patients are less likely to receive indicated procedures and medical therapies.

Entities:  

Mesh:

Year:  2004        PMID: 15522470     DOI: 10.1016/j.ehj.2004.08.006

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  29 in total

Review 1.  Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Authors:  Marcelo Perim Baldo; Sérgio Lamêgo Rodrigues; José Geraldo Mill
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

Review 2.  Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.

Authors:  R Weir; J J V McMurray
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

3.  Precipitating Factors for Hospitalization with Heart Failure: Prevalence and Clinical Impact Observations from the Gulf CARE (Gulf aCute heArt failuRe rEgistry).

Authors:  Amar M Salam; Kadhim Sulaiman; Alawi A Alsheikh-Ali; Rajvir Singh; Khalid F AlHabib; Ibrahim Al-Zakwani; Nidal Asaad; Awad Al-Qahtani; Mohammed Al-Jarallah; Wael AlMahmeed; Bassam Bulbanat; Mustafa Ridha; Nooshin Bazargani; Haitham Amin; Ahmed Al-Motarreb; Prashanth Panduranga; Husam AlFaleh; Abdulla Shehab; Jassim Al Suwaidi
Journal:  Med Princ Pract       Date:  2019-09-16       Impact factor: 1.927

Review 4.  Therapies to prevent heart failure post-myocardial infarction.

Authors:  Kevin L Thomas; Eric J Velazquez
Journal:  Curr Heart Fail Rep       Date:  2005-12

5.  Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction.

Authors:  Joanna Gierach; Marcin Gierach; Iwona Świątkiewicz; Marek Woźnicki; Grzegorz Grześk; Adam Sukiennik; Marek Koziñski; Jacek Kubica
Journal:  Heart Vessels       Date:  2014-12-25       Impact factor: 2.037

Review 6.  Diabetes and heart failure in the post-myocardial infarction patient.

Authors:  Jerry D Estep; David Aguilar
Journal:  Curr Heart Fail Rep       Date:  2006-12

Review 7.  Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction.

Authors:  Robin A P Weir; John J V McMurray
Journal:  Curr Heart Fail Rep       Date:  2006-12

Review 8.  [Stem cell therapy in acute myocardial infarction].

Authors:  M Brehm; E Darrelmann; B E Strauer
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

Review 9.  Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials.

Authors:  George V Moukarbel; Scott D Solomon
Journal:  Curr Heart Fail Rep       Date:  2008-12

Review 10.  Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure.

Authors:  Shannon M Dunlay; Véronique L Roger
Journal:  Curr Heart Fail Rep       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.